Clinical trials: Lenalidomide, completed
Multiple Myeloma
Combination of Lenalidomide and Dexamethasone in Treatment of Multiple Myeloma
In this study for elderly myeloma patients lenalidomide plus low-dose dexamethasone until progression is being compared with age-adjusted tandem high-dose melphalan 140 mg/m² augmented by induction with 3 cycles of lenalidomide…
- Trial name
- DSM XIII (NCT01090089)
- Testing
- Lenalidomide, Dexamethasone, Lenalidomide, Dexamethasone, PBSCT
- Where
- 31 sites in Germany
- Volunteers
- 348 people
- Sponsor
- Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH
Multiple Myeloma
Non-interventional Study on Time to Response and Quality of Life in Relapsed/Refractory Multiple Myeloma When Treated With Lenalidomide in Second Line
The purpose of this study is to quantify the burden of treatment in relapsed or refractory multiple myeloma in patients receiving lenalidomide after one prior treatment for myeloma.
- Trial name
- NCT01430546
- Where
- Sweden
- Volunteers
- 133 people
- Sponsor
- Hareth Nahi
Patients With Multiple Myeloma Experiencing a, First or Second Relapse
Study on the Safety, Anti-tumor Activity and Pharmacology of IPH2101 Combined With Lenalidomide in Patients With Multiple Myeloma Experiencing a First or Second Relapse
The primary objective of the clinical study is to evaluate, in patients who experience a first or second relapse of their multiple myeloma, the safety of escalating doses of IPH2101 combined with lenalidomide
- Trial name
- KIRIMID (NCT01217203)
- Testing
- IPH2101 combined to lenalidomide
- Where
- 6 sites in United States
- Volunteers
- 15 people
- Sponsor
- Innate Pharma
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Sonidegib and Lenalidomide After Stem Cell Transplant in Treating Patients With Multiple Myeloma
This phase II trial studies how well sonidegib and lenalidomide after stem cell transplant works in treating patients with multiple myeloma.
- Trial name
- NCT02086552
- Testing
- Laboratory Biomarker Analysis, Lenalidomide, Sonidegib
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Mayo Clinic
Refractory Primary-cutaneous Large B-cell Lymphoma (Leg-type)
Lenalidomide in Relapsed or Refractory Primary-cutaneous Large B-cell Lymphoma Leg-type : Multicentre Prospective Phase II Single Arm Trial of the French Study Group of Cutaneous Lymphoma
In spite of high initial response rate after a first line treatment by R-polychemotherapy, cutaneous but also extra-cutaneous recurrences occur after 2 years in about half of the patients with PCBCL-LT.
- Trial name
- REV-LEG (NCT01556035)
- Testing
- Lenalidomide
- Where
- 24 sites in France
- Volunteers
- 19 people
- Sponsor
- University Hospital, Bordeaux
Multiple Myeloma
A Phase III Trial on the Effect of Elotuzumab in VRD Induction /Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma
Trial in patients with newly diagnosed myeloma to evaluate the effect of elotuzumab in induction and consolidation therapy with bortezomib/lenalidomide/dexamethasone and in lenalidomide maintenance treatment
- Trial name
- GMMG-HD6 (NCT02495922)
- Testing
- elotuzumab, Lenalidomide, Bortezomib
- Where
- 68 sites in Germany
- Volunteers
- 564 people
- Sponsor
- University of Heidelberg Medical Center
Relapsed and/or Refractory Multiple Myeloma
A Study of Ixazomib Plus Lenalidomide and Dexamethasone in Adult Japanese Participants With Relapsed and/or Refractory Multiple Myeloma
The purpose of this study is to evaluate the efficacy and safety of ixazomib plus lenalidomide and dexamethasone in Japanese participants with relapsed and/or refractory multiple myeloma (RRMM).
- Trial name
- NCT02917941
- Testing
- Ixazomib, Lenalidomide, Dexamethasone
- Where
- 21 sites in Japan
- Volunteers
- 34 people
- Sponsor
- Takeda
Multiple Myeloma
WT1 Vaccine Treatment of Patients With Multiple Myeloma After Autologous Stem Cell Transplantation
The purpose of this trial is to assess the immune response after vaccination with a peptide vaccine called galinpepimut-S (or GPS) in a type of blood cancer called multiple myeloma.
- Trial name
- NCT01827137
- Testing
- Galinpepimut-S, GM-CSF, Montanide
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Sellas Life Sciences Group
MDS, AML
Lenalidomide in High-risk MDS and AML With Del(5q) or Monosomy 5
The aim of this study is to investigate the efficacy of lenalidomide in high risk MDS or AML with chromosome 5 aberrations.
- Trial name
- NCT00761449
- Testing
- lenalidomide
- Where
- 18 sites in Denmark, Norway and 1 more
- Volunteers
- 28 people
- Sponsor
- Nordic MDS Group
Renal Failure, Multiple Myeloma
Lenalidomide & High Dose Dexamethasone for Untreated Multiple Myeloma Renal Failure Patients
Primary: To validate the initial dosing recommendations for newly diagnosed MM (Mutiple Myeloma) patients with various degrees of renal failure using pharmacokinetic studies Secondary: To evaluate the safety of lenalidomide and…
- Trial name
- NCT01270932
- Testing
- Lenalidomide and Dexamethasone
- Where
- Canada
- Volunteers
- 28 people
- Sponsor
- University Health Network, Toronto
Multiple Myeloma
A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy
The purpose of this study to determine if the addition of daratumumab to bortezomib + lenalidomide + dexamethasone (VRd) will improve overall minimal residual disease (MRD) negativity rate compared with VRd alone.
- Trial name
- NCT03652064
- Testing
- Daratumumab, Bortezomib, Lenalidomide
- Where
- 114 sites in United States, Brazil and 11 more
- Volunteers
- 395 people
- Sponsor
- Janssen Research & Development, LLC
Hodgkin Disease
Lenalidomide in Relapsed or Refractory Classical Hodgkin Lymphoma
The purpose of this study is to determine the efficacy of lenalidomide in the treatment of relapsed or refractory classic Hodgkin lymphoma(cHL).
- Trial name
- NCT00540007
- Testing
- Lenalidomide
- Where
- 5 sites in United States
- Volunteers
- 80 people
- Sponsor
- Washington University School of Medicine
Leukemia
5-Azacytidine With Lenalidomide in Patients With High Risk Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)
The goal of Phase 1 of this clinical research study is to find the highest tolerable dose of lenalidomide that can be given in combination with azacitidine to patients with MDS or AML.
- Trial name
- NCT01038635
- Testing
- 5-Azacytidine, Lenalidomide
- Where
- United States
- Volunteers
- 94 people
- Sponsor
- M.D. Anderson Cancer Center
Multiple Myeloma
A Dose Escalation Study of the Combination of Lenalidomide (Revlimid®), Dexamethasone and Cyclophosphamide in Patients Refractory or Relapsing From Stable Disease With Multiple Myeloma
The purpose of this study is to determine the maximum tolerated dose (MTD) and to evaluate the safety of cyclophosphamide when given on days 1 and 8 in a 28 day cycle in doses starting at 300mg ranging to 700mg in combination…
- Trial name
- CRD (NCT00915408)
- Testing
- Lenalidomide, Dexamethasone, Cyclophosphamide
- Where
- 2 sites in United Kingdom
- Volunteers
- 32 people
- Sponsor
- King's College Hospital NHS Trust
Anaplastic Large Cell Lymphoma, ALK-Negative, Recurrent Anaplastic Large Cell Lymphoma
Lenalidomide Therapy After Chemotherapy & Stem Cell Transplant in Treating Chemotherapy Resistan Non-Hodgkin Lymphoma
This phase I/II trial studies the side effects and best dose of lenalidomide when given after combination chemotherapy with or without rituximab and stem cell transplant and to see how well it works in treating patients with…
- Conditions
- Anaplastic Large Cell Lymphoma, ALK-Negative, Recurrent Anaplastic Large Cell Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma
- Trial name
- NCT01035463
- Testing
- Autologous Hematopoietic Stem Cell Transplantation, Carmustine, Cytarabine
- Where
- 3 sites in United States
- Volunteers
- 74 people
- Sponsor
- University of Nebraska
Melanoma, Neoplasm Metastasis
Study to Compare the Efficacy and Safety of Two CC-5013 Dose Regimens in Subjects With Metastatic Malignant Melanoma
Subjects are randomized to one of two treatment arms. All subjects are screened for eligibility within 28 days prior to randomization. The study consists of a treatment phase and a follow-up phase.
- Trial name
- NCT00055562
- Testing
- CC 5013
- Where
- 31 sites in United States, Canada
- Volunteers
- 274 people
- Sponsor
- Celgene Corporation
Primary Plasma Cell Leukemia
Lenalidomide and Dexamethasone in Primary Plasma Cell Leukemia
This is an open label, multicenter, exploratory, single arm, two-stage study aiming to explore efficacy and safety of lenalidomide and dexamethasone combination (LD) as first line therapy in previously untreated patients with…
- Trial name
- NCT01553357
- Testing
- Lenalidomide, dexamethasone
- Where
- Italy
- Volunteers
- 23 people
- Sponsor
- IRCCS Centro di Riferimento Oncologico della Basilicata
Lymphoma
Lenalidomide With or Without Rituximab After Standard Chemotherapy in Treating Patients With Diffuse Large B-Cell Non-Hodgkin Lymphoma
RATIONALE: Lenalidomide may stop the growth of cancer cells by blocking blood flow to the cancer. It may also stimulate the immune system in different ways and stop cancer cells from growing.
- Trial name
- NCT00765245
- Testing
- Lenalidomide, Rituximab
- Where
- 4 sites in United States
- Volunteers
- 44 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Leukemia, Lymphoma
Rituximab, Pentostatin, Cyclophosphamide, and Lenalidomide in Treating Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread.
- Trial name
- NCT00602836
- Testing
- Rituximab, Cyclophosphamide, Lenalidomide
- Where
- 3 sites in United States
- Volunteers
- 45 people
- Sponsor
- Mayo Clinic
Multiple Myeloma
Monitoring of Deep of Response During Lenalidomide Maintenance in MM Patients Achieving at Least Very Good Partial Response (MRD)
This is an italian multicenter study to determine whether maintenance treatment with Lenalidomide-based regimen significantly increases the rate of molecular remission in patients achieving at least a VGPR after therapy with new…
- Trial name
- MRD (NCT03433365)
- Testing
- MRD analysis
- Where
- Italy
- Volunteers
- 70 people
- Sponsor
- Fondazione EMN Italy Onlus